Wellnex Life (ASX:WNX) has reported a significant turnaround in its financial performance for the six months ended Dec. 31, 2025, with H1 FY26 EBITDA rising $2.4 million compared to the prior year and gross margins increasing from 22.8% to 31.3%.
December 2025 EBITDA was up $0.7 million year-on-year, supported by lower operating costs, while the Group closed Q2 FY26 at breakeven.
The company's Pain Away brand maintained its market position with $3.3 million in quarterly sales and a 7.6% improvement in gross margin; heat patches grew 25% in Pharmacy, lifting market share to 18.5%, and roll-ons grew 17%, with two SKUs ranking #1 and #3 ahead of a third roll-on launch planned for April.
Distribution expanded with Priceline launching five new SKUs, three major pharmacy wholesalers confirming four NPD launches each, and Costco Australia and New Zealand set to trial an exclusive heat patch.
Wellnex is also enhancing its contract manufacturing processes to improve operational efficiency and commercial value delivery.
Entering H2 FY26, the company signals increased stability and a clear path to consistent performance and long-term shareholder value.